DeuteRx

DeuteRx is a biotechnology company focused on research and development, dedicated to improving racemic small molecule marketed drugs and drug candidates suitable for patients with various therapeutic indications. Its leading projects include DRX-065 for the treatment of Adrenoleukodystrophy (ALD); DRX-164 for the treatment of multiple myeloma and immuno-oncology; and DRX-184 for the treatment of central nervous system diseases.